Last reviewed · How we verify
NCT05956015
Albumin Catabolic Rate Measured by a Stable Isotope
NA trial testing stable isotopes in Liver Disease Chronic in 24 participants. Not yet recruiting.
30 June 2028
Quick facts
| Lead sponsor | Ake Norberg |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 24 |
| Start date | 28 August 2023 |
| Primary completion | 30 June 2028 |
| Estimated completion | 31 December 2028 |
| Sites | 1 location across Sweden |
Drugs / interventions tested
- stable isotopes — full drug profile →
Conditions studied
- Liver Disease Chronic — all drugs for Liver Disease Chronic →
Sponsor
Ake Norberg
Who can join
40 and older, any sex, with Liver Disease Chronic. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this physiological study is to compare albumin catabolic rate measured by a stable isotope labeled amino acid in healthy volunteers and in patients with liver disease. At steady state synthesis and catabolism or degradation are equal. The primary questions it aims to answer are: * Is albumin catabolic rate lower in patients with liver disease? * Is albumin catabolic rate measured by stable isotopes in volunteers like historical controls measured by radio-iodinated albumin at the investigator's laboratory or elsewhere? Subjects will be given an oral dose of the deuterium labeled amino acid phenylalanine that will be incorporated by the liver in newly synthetized albumin molecules, and blood samples will be taken over 12 weeks to determine the catabolic rate of albumin.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05956015
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Liver Disease Chronic
Currently open trials in the same condition.
- NCT07487623 — Evaluation of the Hepatoprotective Effects of a Nutritional Supplement in Patients With Liver Disease Secondary to Chron · NA · recruiting
- NCT05205954 — HepHospital: A Pilot Trial of a Hepatology Home Hospital Intervention for Patients With Advanced Liver Disease · NA · recruiting
Other Ake Norberg trials
Trials by the same sponsor.
- NCT03441035 — Albumin Mass Balance in Liver Transplantation · unknown
- NCT01686776 — A Prospective Validation Study of Albumin Kinetics With Tracer 123 I-HSA · Phase 3 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05956015 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ake Norberg
- Last refreshed: 25 July 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05956015.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing